|
1
|
Frid MG, Brunetti JA, Burke DL, Carpenter
TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N and
Stenmark KR: Hypoxia-induced pulmonary vascular remodeling requires
recruitment of circulating mesenchymal precursors of a
monocyte/macrophage lineage. Am J Pathol. 168:659–669. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hall S, Brogan P, Haworth SG and Klein N:
Contribution of inflammation to the pathology of idiopathic
pulmonary arterial hypertension in children. Thorax. 64:778–783.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pinto RF, Higuchi ML and Aiello VD:
Decreased numbers of T-lymphocytes and predominance of recently
recruited macrophages in the walls of peripheral pulmonary arteries
from 26 patients with pulmonary hypertension secondary to
congenital cardiac shunts. Cardiovasc Pathol. 13:268–275. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heath D and Edwards JE: The pathology of
hypertensive pulmonary vascular disease; a description of six
grades of structural changes in the pulmonary arteries with special
reference to congenital cardiac septal defects. Circulation.
18:533–547. 1958. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perros F, Dorfmüller P, Montani D, Hammad
H, Waelput W, Girerd B, Raymond N, Mercier O, Mussot S,
Cohen-Kaminsky S, et al: Pulmonary lymphoid neogenesis in
idiopathic pulmonary arterial hypertension. Am J Respir Crit Care
Med. 185:311–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soon E, Holmes AM, Treacy CM, Doughty NJ,
Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin
P, et al: Elevated levels of inflammatory cytokines predict
survival in idiopathic and familial pulmonary arterial
hypertension. Circulation. 122:920–927. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Frutos S, Spangler R, Alò D and Bosc
LV: NFATc3 mediates chronic hypoxia-induced pulmonary arterial
remodeling with alpha-actin up-regulation. J Biol Chem.
282:15081–15089. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bonnet S, Rochefort G, Sutendra G, Archer
SL, Haromy A, Webster L, Hashimoto K, Bonnet SN and Michelakis ED:
The nuclear factor of activated T cells in pulmonary arterial
hypertension can be therapeutically targeted. Proc Natl Acad Sci
USA. 104:11418–11423. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Said SI, Hamidi SA and Bosc L Gonzalez:
Asthma and pulmonary arterial hypertension: Do they share a key
mechanism of pathogenesis? Eur Respir J. 35:730–734. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rowlands DJ, Islam MN, Das SR, Huertas A,
Quadri SK, Horiuchi K, Inamdar N, Emin MT, Lindert J, Ten VS,
Bhattacharya S and Bhattacharya J: Activation of TNFR1 ectodomain
shedding by mitochondrial Ca2+ determines the severity of
inflammation in mouse lung microvessels. J Clin Invest.
121:1986–1999. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu M, Han ZB, Liu JF, Wang YW, Zhang JZ,
Li CT, Xin PL, Han ZC and Zhu XP: Serum-free media and the
immunoregulatory properties of mesenchymal stem cells in vivo and
in vitro. Cell Physiol Biochem. 33:569–580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang ZX, Han ZB, Ji YR, Wang YW, Liang L,
Chi Y, Yang SG, Li LN, Luo WF, Li JP, et al: CD106 identifies a
subpopulation of mesenchymal stem cells with unique
immunomodulatory properties. PLoS One. 8:e593542013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Le Blanc K, Rasmusson I, Sundberg B,
Gӧtherstrӧm C, Hassan M, Unzel M and Ringdén O: Treatment of severe
acute graft-versus-host disease with third party haploidentical
mesenchymal stem cells. Lancet. 363:1439–1441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zappia E, Casazza S, Pedemonte E,
Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti
F, Frassoni F, Mancardi G and Uccelli A: Mesenchymal stem cells
ameliorate experimental autoimmune encephalomyelitis inducing
T-cell anergy. Blood. 106:1755–1761. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baber SR, Deng W, Master RG, Bunnell BA,
Taylor BK, Murthy SN, Hyman AL and Kadowitz PJ: Intratracheal
mesenchymal stem cell administration attenuates
monocrotaline-induced pulmonary hypertension and endothelial
dysfunction. Am J Physiol Heart Circ Physiol. 292:H1120–H1128.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luan Y, Zhang X, Kong F, Cheng GH, Qi TG
and Zhang ZH: Mesenchymal stem cell prevention of vascular
remodeling in high flow-induced pulmonary hypertension through a
paracrine mechanism. Int Immunopharmacol. 14:432–437. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X,
Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ and Han ZC: Isolation
and characterization of human umbilical cord mesenchymal stem cells
with hematopoiesis-supportive function and other potentials.
Haematologica. 91:1017–1026. 2006.PubMed/NCBI
|
|
18
|
Matsuda Y, Hoshikawa Y, Ameshima S, Suzuki
S, Okada Y, Tabata T, Sugawara T, Matsumura Y and Kondo T: Effects
of peroxisome proliferator-activated receptor gamma ligands on
monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki
Gakkai Zasshi. 43:283–288. 2005.(In Japanese). PubMed/NCBI
|
|
19
|
Maruyama H, Watanabe S, Kimura T, Liang J,
Nagasawa T, Onodera M, Aonuma K and Yamaguchi I: Granulocyte
colony-stimulating factor prevents progression of
monocrotaline-induced pulmonary arterial hypertension in rats. Circ
J. 71:138–143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zangiabadi A, De Pasquale CG and Sajkov D:
Pulmonary hypertension and right heart dysfunction in chronic lung
disease. Biomed Res Int. 2014:7396742014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patel R, Aronow WS, Patel L, Gandhi K,
Desai H, Kaul D and Sahgal SP: Treatment of pulmonary hypertension.
Med Sci Monit. 18:RA31–RA39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pittenger MF, Mackay AM, Beck SC, Jaiswal
RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and
Marshak DR: Multilineage potential of adult human mesenchymal stem
cells. Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL
and Chen TH: Isolation of multipotent mesenchymal stem cells from
umbilical cord blood. Blood. 103:1669–1675. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fukuchi Y, Nakajima H, Sugiyama D, Hirose
I, Kitamura T and Tsuji K: Human placenta-derived cells have
mesenchymal stem/progenitor cell potential. Stem Cells. 22:649–658.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zuk PA, Zhu M, Mizuno H, Huang J, Futrell
JW, Katz AJ, Benhaim P, Lorenz HP and Hedrick MH: Multilineage
cells from human adipose tissue: Implications for cell-based
therapies. Tissue Eng. 7:211–228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baksh D, Yao R and Tuan RS: Comparison of
proliferative and multilineage differentiation potential of human
mesenchymal stem cells derived from umbilical cord and bone marrow.
Stem Cells. 25:1384–1392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jun D, Garat C, West J, Thorn N, Chow K,
Cleaver T, Sullivan T, Torchia EC, Childs C, Shade T, et al: The
pathology of bleomycin-induced fibrosis is associated with loss of
resident lung mesenchymal stem cells that regulate effector T-cell
proliferation. Stem Cells. 29:725–735. 2011. View Article : Google Scholar : PubMed/NCBI
|
